[{"address1": "11400 West Olympic Boulevard", "address2": "Suite 200", "city": "Los Angeles", "state": "CA", "zip": "90064", "country": "United States", "phone": "310 651 8041", "website": "https://www.immixbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.", "fullTimeEmployees": 18, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ilya  Rachman M.B.A., M.D., MBA, Ph.D.", "age": 51, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 712500, "exercisedValue": 0, "unexercisedValue": 120332}, {"maxAge": 1, "name": "Mr. Gabriel  Morris B.A.", "age": 37, "title": "CFO & Director", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 712500, "exercisedValue": 0, "unexercisedValue": 461582}, {"maxAge": 1, "name": "Dr. Graham  Ross FFPM, M.D.", "age": 64, "title": "Chief Medical Officer & Head of Clinical Development", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 88593, "exercisedValue": 0, "unexercisedValue": 5100}, {"maxAge": 1, "name": "Mr. Sean  Senn J.D., M.B.A., M.Sc., MBA, MSc", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.", "age": 77, "title": "Scientific Co-Founder", "yearBorn": 1947, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Marks MBBS, Ph.D.", "title": "Chief Medical Officer of Cell Therapy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.7, "open": 2.74, "dayLow": 2.67, "dayHigh": 2.9, "regularMarketPreviousClose": 2.7, "regularMarketOpen": 2.74, "regularMarketDayLow": 2.67, "regularMarketDayHigh": 2.9, "payoutRatio": 0.0, "beta": 0.225, "forwardPE": -5.2181816, "volume": 529649, "regularMarketVolume": 529649, "averageVolume": 297860, "averageVolume10days": 760100, "averageDailyVolume10Day": 760100, "bid": 2.07, "ask": 3.45, "bidSize": 2, "askSize": 2, "marketCap": 94811928, "fiftyTwoWeekLow": 1.34, "fiftyTwoWeekHigh": 3.2, "allTimeHigh": 8.68, "allTimeLow": 0.68, "fiftyDayAverage": 2.2437, "twoHundredDayAverage": 2.12813, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 72158752, "profitMargins": 0.0, "floatShares": 19376811, "sharesOutstanding": 33035515, "sharesShort": 521769, "sharesShortPriorMonth": 369043, "sharesShortPreviousMonthDate": 1756425600, "dateShortInterest": 1759190400, "sharesPercentSharesOut": 0.016, "heldPercentInsiders": 0.35708, "heldPercentInstitutions": 0.08456001, "shortRatio": 3.33, "shortPercentOfFloat": 0.024500001, "impliedSharesOutstanding": 33035515, "bookValue": 0.164, "priceToBook": 17.499998, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -23126540, "trailingEps": -0.77, "forwardEps": -0.55, "enterpriseToEbitda": -3.05, "52WeekChange": 0.79375005, "SandP52WeekChange": 0.13837254, "quoteType": "EQUITY", "currentPrice": 2.87, "targetHighPrice": 8.0, "targetLowPrice": 8.0, "targetMeanPrice": 8.0, "targetMedianPrice": 8.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 11637945, "totalCashPerShare": 0.404, "ebitda": -23659982, "totalDebt": 1042802, "quickRatio": 1.163, "currentRatio": 1.231, "debtToEquity": 22.411, "returnOnAssets": -0.66849, "returnOnEquity": -1.6204, "freeCashflow": -4037955, "operatingCashflow": -12507206, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "IMMX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "twoHundredDayAverageChangePercent": 0.3486018, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-12-16", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1760744246, "regularMarketTime": 1760731201, "exchange": "NCM", "messageBoardId": "finmb_417356223", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 297860, "fiftyTwoWeekLowChange": 1.5299999, "fiftyTwoWeekLowChangePercent": 1.1417909, "fiftyTwoWeekRange": "1.34 - 3.2", "fiftyTwoWeekHighChange": -0.33000016, "fiftyTwoWeekHighChangePercent": -0.10312505, "fiftyTwoWeekChangePercent": 79.37501, "regularMarketChangePercent": 6.29629, "regularMarketPrice": 2.87, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1639665000000, "postMarketChangePercent": -0.696863, "postMarketPrice": 2.85, "postMarketChange": -0.02, "regularMarketChange": 0.17, "regularMarketDayRange": "2.67 - 2.9", "earningsTimestampStart": 1754942400, "earningsTimestampEnd": 1755288000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.77, "epsForward": -0.55, "epsCurrentYear": -0.675, "priceEpsCurrentYear": -4.2518516, "fiftyDayAverageChange": 0.62629986, "fiftyDayAverageChangePercent": 0.27913707, "twoHundredDayAverageChange": 0.7418699, "shortName": "Immix Biopharma, Inc.", "longName": "Immix Biopharma, Inc.", "displayName": "Immix Biopharma", "trailingPegRatio": null, "__fetch_time": "2025-10-18"}]